Debbie Frogozo, PA
Physician Assistant · San Diego, CANPI 1982814638
Payments from drug & device makers
Across 185 payments — averaging $20.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$534
- Lilly USA, LLC$380
- AbbVie$377
- Novo Nordisk$278
- GSK$222
- Antares Pharma, Inc.$164
- plus $2K from 36 others
What the payments were for
- Food & beverage$3,85799%
- Education$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 28 | $534 |
| Lilly USA, LLC | 18 | $380 |
| AbbVie | 17 | $377 |
| Novo Nordisk | 16 | $278 |
| GSK | 10 | $222 |
| Antares Pharma, Inc. | 6 | $164 |
| Boston Scientific | 6 | $146 |
| Sanofi Pasteur Inc. | 7 | $144 |
| Amgen(2 entities) | 6 | $130 |
| Boehringer Ingelheim | 6 | $122 |
| Seqirus USA Inc | 7 | $119 |
| Astellas Pharma US Inc | 5 | $116 |
| Johnson & Johnson | 4 | $89 |
| Merz Pharmaceuticals, LLC | 2 | $82 |
| Vanda Pharmaceuticals Inc. | 3 | $75 |
| Abiomed | 3 | $63 |
| Abbott | 3 | $62 |
| Sanofi-aventis U.S. LLC | 3 | $60 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $54 |
| Exact Sciences | 2 | $44 |
| Novartis | 2 | $44 |
| Biohaven Pharmaceuticals, Inc. | 2 | $43 |
| Currax Pharmaceuticals LLC | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Stryker | 1 | $38 |
| Medtronic | 1 | $30 |
| Halozyme Inc | 2 | $29 |
| Cranial Technologies, Inc | 2 | $29 |
| Microtransponder, Inc. | 1 | $28 |
| Alk-abello, Inc | 1 | $27 |
| Si-bone, Inc. | 1 | $25 |
| Dexcom, Inc. | 1 | $24 |
| Tactile Systems Technology Inc | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Nevro Corp. | 1 | $20 |
| AstraZeneca | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Eisai Inc. | 1 | $17 |
| Bayer | 1 | $14 |
| Neurelis, Inc. | 1 | $12 |
How this compares
$3,882 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 38 | $45,388 |
| MounjaroTirzepatide | 37 | $41,995 |
| XareltoRivaroxaban | 34 | $39,187 |
| RybelsusSemaglutide | 15 | $29,936 |
| TrulicityDulaglutide | 19 | $25,794 |
| EliquisApixaban | 14 | $18,917 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 85 | $3,398 |
| Rosuvastatin Calcium | 94 | $2,761 |
| Wixela InhubFluticasone Propion/Salmeterol | 13 | $2,685 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $1,883 |
| Valsartan | 75 | $1,644 |
| Levothyroxine Sodium | 132 | $1,244 |
| Ibandronate Sodium | 13 | $1,095 |
| Atorvastatin Calcium | 107 | $969 |
| Tamsulosin Hcl | 61 | $933 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $278 | $75,32453 claims |
| Lilly USA, LLCMounjaro, Trulicity | $380 | $67,78956 claims |
| Johnson & JohnsonXarelto | $89 | $39,18734 claims |
| PfizerEliquis | $534 | $18,91714 claims |
| AbbVieSynthroid | $377 | $57719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.
Other physician assistant in San Diego
- Jeremy AdlerSan Diego$82K
- Anne DenslowSan Diego$43K
- Kathryn SmileySan Diego$33K
- John QuigleyDowney$2.9M
- Andrea NguyenIrvine$1M
- Mikhail AlperMadera$889K
- Erin JensenUpland$716K
- Franklin ClineSacramento$458K
- Carla CrespoMarina del Rey$297K
- Katherine OsakiEl Centro$274K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.